Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. (22nd February 2018)

• Record Type: Journal Article
• Authors: Rosner, Samuel; Kwong, Erica; Shoushtari, Alexander N.; Friedman, Claire F.; Betof, Allison S.; Brady, Mary Sue; Coit, Daniel G.; Callahan, Margaret K.; Wolchok, Jedd D.; Chapman, Paul B.; Panageas, Katherine S.; Postow, Michael A.
• Is Part Of: Cancer medicine. Volume 7:Number 3(2018:Mar.)
• Page Start: 690
• Page End: 697
• Publication Date: 2018-02-22
• Subjects: Biomarkers -- immunotherapy -- ipilimumab -- nivolumab -- PD‐1 -- pembrolizumab -- prognosis; 616.994005
• DOI: 10.1002/cam4.1356
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: Both the combination of nivolumab + ipilimumab and single‐agent anti‐PD‐1 immunotherapy have demonstrated survival benefit for patients with advanced melanoma. As the combination has a high rate of serious side effects, further analyses in randomized trials of combination versus anti‐PD‐1 immunotherapy are needed to understand who benefits most from the combination. Clinical laboratory values that were routinely collected in randomized studies may provide information on the relative benefit of combination immunotherapy. To prioritize which clinical laboratory factors to ultimately explore in these randomized studies, we performed a single‐center, retrospective analysis of patients with advanced melanoma who received nivolumab + ipilimumab either as part of a clinical trial ( n = 122) or commercial use ( n = 87). Baseline routine laboratory values were correlated with overall survival (OS) and overall response rate (ORR). Kaplan–Meier estimation and Cox regression were performed. Median OS was 44.4 months, 95% CI (32.9, Not Reached). A total of 110 patients (53%) responded (CR/PR). Significant independent variables for favorable OS included the following: high relative eosinophils, high relative basophils, low absolute monocytes, low LDH, and a low neutrophil‐to‐lymphocyte ratio. These newly identified factors, along with those previously reported to be associated with anti‐PD‐1 monotherapy outcomes, should be studied in the randomized trials of nivolumab + ipilimumab versus anti‐PD‐1 monotherapies to determine whether they help define the patients who benefit most from the combination versus anti‐PD‐1 alone. Abstract : The combination of nivolumab and ipilimumab is a highly effective treatment for patients with melanoma, and little is known about the patients who do the best after treatment. For the first time, we report basic clinical laboratory variables which are associated with overall survival following treatment.